Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Comparable outcomes in patients aged ≥70 vs. 70 undergoing allogeneic transplantation with fludarabine and melphalan conditioning and post-transplant cyclophosphamide

View Full Paper
Ask AI
Bookmark
Share

Authors

ACAndy ChenRCRachel C. CookJLJessica T. Leonard

Discussion

Loading...

Member takes

Overview

Observational analysis shows comparable survival and toxicity in patients ≥70 and <70 undergoing hematopoietic cell transplant using melphalan conditioning.

Key Points

  • Median overall survival in patients ≥70 was 92%, not significantly different from 88% in those <70.
  • Acute graft-versus-host disease rates and severity were similar across both age groups, indicating tolerability.
  • Retrospective analysis at a single center evaluated transplant outcomes and complications in AML/MDS patients.
  • Highlights the importance of considering older adults for hematopoietic cell transplant in the setting of malignancies.

Cite This Study

Chen et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d8bdhttps://doi.org/10.1182/blood-2025-6085
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Allograft for myeloid malignancies in the year of 70 years old and beyond: No impact of pre-graft immune, nutritional and inflammatory status on outcome.2025
  2. 2Superior long-term outcomes with fludarabine and melphalan reduced intensity regimen in older AML/MDS patients undergoing allogeneic stem cell transplantation: An analysis of CIBMTR data2025
  3. 3Outcomes and associated factors after melphalan 140 mg/m² autologous hematopoietic cell transplantation for multiple myeloma in patients over 70 years of age2025
  4. 4Comparative outcomes of fludarabine-melphalan versus fludarabine-busulfan reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies: A systematic review and meta-analysis2025
  5. 5Comparison of 80 mg/kg vs. 100 mg/kg post-transplant cyclophosphamide dose with flu/mel and allogeneic transplant: Less is not more2025